Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon Research Institute of Colorado ...

SynKIR™-310 relies on Verismo's unique KIR-CAR platform and proprietary CD19 binder (DS191). SynKIR™-310 targets CD19, similarly to the commercially approved CAR T therapies, with the added ...

Starbucks is reversing its open-door policy after almost seven years, now requiring that people make a purchase if they want to hang out at its coffee shops or use its restrooms. The coffee giant ...

Starbucks said later this month it will begin requiring purchases in order to hang out in the company's cafes or use its bathrooms. The company said it has heard from employees that “there is a ...

Starbucks is a pioneer of the “second wave” coffee movement, with its origins in Seattle near the famous Pike Place Market. Starbucks stock price has seen tremendous growth since its 1992 IPO ...

Credit: Volha_R/Shutterstock. Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon ...

Clinical-stage CAR T company dosed first patient for Phase 1 trial to evaluate SynKIR™-310, a new drug candidate for relapsed/refractory B cell Non-Hodgkin Lymphomas PHILADELPHIA, Jan. 10, 2025 ...